Life Sciences Archive » August, 2023

Life Sciences - August, 2023

319 articles

• Fed. Circ. Puts More Patents At Risk Of Double-Patenting Ax
• Plan To Reschedule Pot Buoys Industry But Angers Reformers
• Rite Aid Atty's 'Money Grab' Comments Don't Justify New Trial
• Trans Teens Say 11th Circ. Ruling Doesn't Affect Georgia Case
• The Basics Of Being A Knowledge Management Attorney
• 10th Circ. Won't Reconsider Nixing Military COVID Vax Suit
• Ousted Sales Rep Accuses Zimmer Of Age, Gender Bias
• The Fed. Circ. In August: New Claim Constructions In IPR
• Judge Won't Step Into Attys' Flint Settlement Fee Spat
• Challenging Standing In Antitrust Classes: The Uninjured
• $3M Judgment For Conn. Co. Will Be Defrayed By Credits
• Purdue Ch. 11 Case Exemplifies Need For 3rd-Party Releases
• Gilead Urges Calif. Appeals Court To Toss HIV Drug Claims
• Calif. Urges 9th Circ. To Mirror 1st Circ. Insulin Suit Ruling
• Medtronic Unit's Insulin Device Exposes User Data, Suit Says
• Suboxone Buyers Can't Narrow Product Market Ahead Of Trial
• Mallinckrodt Cleared To Tap Into $250M Of Ch. 11 Financing
• IVIG Patients Can't Get Class Cert. In AmerisourceBergen Suit
• Pharma Cos. Caused Zantac-Linked Cancers, Conn. Suit Says
• HHS Sends New Pot Scheduling Recommendation To DEA
• What Big Tobacco's Cannabis Investments Mean For Market
• Michigan Gov. Eyes Paid Leave, Clean Energy For Fall Agenda
• These Firms Have The Most Women In Equity Partnerships
• Novo Nordisk Snags Obesity-Focused Biz For Up To $515M
• HHS Fans Legal Flames With Medicare Drug Negotiation Picks
• 11th Circ. Upholds $40M Sanctions Against Ga. Pharma Co.
• US Chamber Backs Amgen In FTC's $27.8B Merger Challenge
• Canadian Cos. Say Scammer Stole $1M For Fake Refinery Deal
• DC Circ. Says FDA Botched Part Of E-Cig Review
• CVS, Others Say Consumers Can't 'Free Ride' HIV Drugs Deal
• Fla. Medical Supplier Lincare Pays $29M In Medicare FCA Suit
• Dems Want FDA To Work With USPTO On Drug Pricing
• Biopharma Co. Catalent Cuts Deal With Activist Elliott
• Gilead, Generics Co. Beat HIV Drug Antitrust Suit For Now
• To Hire And Keep Top Talent, Think Beyond Compensation
• Ex-Mylan CIO Waives Atty Conflict For Insider Trading Case
• A Deep Dive Into Law360 Pulse's Women In Law Report
• How Merger Review Overhaul Could Affect Health Industry
• Fla. Judge Says Geneticist Wasn't OK'd To Sell Cloned Horses
• Amid Legal Blitz, HHS Reveals 1st Drugs For Negotiations
• Supplement Co. Owner Nets Nearly $550K Win In TM Suit
• 2nd Circ. Revives Investor Suit Against Synergy Pharma Exec
• Pfizer Takes Aim At Moderna COVID Vaccine Patents At PTAB
• FTC Pulls Amgen-Horizon Merger Case, Citing Possible Deal
• Catching Up With Delaware's Chancery Court
• Drug Co. Says Exclusion Doesn't Bar Subpoena Coverage
• What Circuit Split May Mean For FCA Kickback Liability
• Ex-Partners Say They Were Shut Out Of Flint Settlement Fees
• Dickson Minto-Led Centene Selling Circle Health For $1.2B
• Danaher To Buy Life Sciences Co. Abcam In $5.7B Deal
• Mallinckrodt Files Second Ch. 11 To Wipe Out $1.9B Of Debt
• Alnylam, Moderna Agree To COVID Vax Patent Judgment
• AppHarvest Gets $30M In DIP Financing To Get To Ch. 11 Sale
• DC Circ. Won't Revive FTC's Endo-Impax Deal Suit
• Abbott Labs Sued Over Sucralose In Glucerna Health Shakes
• 3rd Circ. Rejects FCA Defense Using 'Single Escobar Factor'
• Sorrento Approved For $105M Scilex Stock Sale In Ch. 11
• AARP Fights Block Of Medicare Drug Price Negotiations
• A Closer Look At China's Landmark Pharma Antitrust Ruling
• AstraZeneca Joins Big Pharma's Offensive On Price Talks
• NJ Judge OKs Blanket Confidentiality In COVID Firing Suit
• Mich. Judge Approves $9.5M Data-Sharing Settlement
• 9th Circ. Says Non-MDL Clients Can Be Part Of Common Fund
• More States Should Join Effort To Close Legal Services Gap
• Taxation With Representation: Kirkland, Skadden
• UK Litigation Roundup: Here's What You Missed In London
• Supplement Co. Gets Versalyte Flavor Suit Trimmed
• W.Va. AG Knocks Out Bulk Of Challenge To Abortion Pill Ban
• Geron Investors' Attys Get $4.3M From $24M Stock-Drop Deal
• Chancery Kills Adamis Investor's Suit From Failed Proxy Fight
• Ex-Lincare CEO Fights Injunction In Trade Secrets Suit
• EPA Pledges Final Ethylene Oxide Rule In Deal With Activists
• Biogen Strikes $9.75M Deal In ERISA 401(k) Investment Suit
• Justices Told Big Pharma Can't Escape Terror-Funding Claims
• McCarter & English Asks For End To Legal Malpractice Suit
• Identifying Trends And Tips In Litigation Financing Disclosure
• Bradley Arant Atty Accused Of Improper Mid-Deposition Texts
• Mich. Can Keep Infant Data While It Appeals Destruction Order
• Bid Protest Spotlight: Personnel Loss, Conflicts, Timeliness
• Justices Urged To Nix Abortion Foes' Bid In Covert-Video Case
• Masimo Hit With Investor Suit Over Revenue Disclosures
• Teva Escapes Ex-Exec's Age Discrimination Case
• 9th Circ. To Review Class Certification In Diabetes Drug Suit
• SC High Court Backs 6-Week Abortion Ban
• High Court Ruling Doesn't Save Christian Clinic's Tossed Suit
• Canadian Tribe's Lawsuit 'Perplexing,' Purdue Tells NY Court
• 2023 Farm Bill Could Follow Md., Minn. Or NY's Lead On Hemp
• DHS Aims To Punt $8.5M Immigration Fee Suit To Claims Court
• A Defendant-Friendly Patent Trend In Central District Of Calif.
• FDA Regulatory Partner Joins King & Spalding In DC
• Boston Biotech Biz Raises $150M In Series B Funding Round
• Mallinckrodt Strikes Creditor Deal For Second Ch. 11 Case
• Walmart's Opioid Deal Advances With States' Participation
• Biotech Firm Can't Nix Researcher's Suit Tied To $35M Buyout
• Va. Judge Won't Order FDA To Maintain Abortion Drug Access
• Amgen, Horizon Say FTC Merger Challenge 'Defies Logic'
• SEC Fines 5 Issuers Over Flawed Late-Filing Disclosures
• Lundbeck Sues USPTO To Extend Patent Term For PTSD Drug
• Fed. Circ. Backs PTAB Invalidation Of Hair Loss Patent
• Judge Clears Court-Appointed Attys Of Wrongful Death Claims
• Decrease In Multiple Petitions Follows USPTO Guidance
• UMich, Striking Grad Union Reach Tentative Agreement
• Tilray Gets Securities Suit Tossed On Reconsideration
• Paraquat, Parkinson's Share Links, Bellwether Judge Hears
• Insurer Can't Escape Covering Sleep Machine Class Actions
• Ga. To Appeal Block On New Hormone Treatment Law
• Best Practices For Atty-Client Privilege In Patent Litigation
• The Pop Culture Docket: Judge Elrod On 'Jury Duty'
• Teva, Glenmark To Pay $305M In Latest DOJ Generics Deal
• DuPont Sells Ownership Interest In Delrin Biz For $1.8B
• Catching Up With Delaware's Chancery Court
• Boehringer Challenges Medicare Drug Price Negotiation Law
• Ga. Justices Say Hospital Can't Fight Bill Nixing Its Opioid Suit
• Vitamin Co.'s Arbitral Win Too Small To Beat Rival's $1.1M Fee
• Teva Wants In On FDA Suit To Defend Dibs On Xifaxan Generic
• Alkermes Gets $194M Award Against Janssen Approved
• Tech Giants, Edwards Lifesciences Fight Fintiv In Calif. Court
• Surgery Monitoring Deal May Violate Kickback Law, HHS Says
• Ex-Lab Co. CEO Gets 27 Years For $187M Medicare Fraud
• ITC Tells ALJ To Rethink Biomolecular Patent Claims
• SPACs Seek Overseas Targets As Domestic Options Shrink
• 4 Firms Guide SPAC Deal For $300M Pregnancy Care Co. Nuvo
• SEC Says Ga. Biz Owner Conned Investors In Crypto Scheme
• 4 Business-Building Strategies For Introvert Attorneys
• Fee Request For Malpractice Suit 'Stunning,' Pharma Biz Says
• Splenda Maker Falsely Touts Diabetes Benefits, Suit Says
• Cleveland Clinic Promotes Akron Unit GC To Compliance Chief
• Foley Hoag Adds Cooley IP Atty In Boston
• Taxation With Representation: Davis Polk, V&E
• Oclaro, Investors Persuade Skeptical Judge To OK $15M Deal
• IP Forecast: Pinterest Looks To Defend DMCA Win At 9th Circ.
• Leadership Redo Sought In Camp Lejeune Suits
• 2 Lose By Default In Suit Alleging Hijack Of Biosciences Co.
• US Sets Up Panel Targeting Mexico's GMO Corn Measures
• DOJ Wants Equal Access To Docs in Ex-Exec's Criminal Case
• PTAB To Eye Cancer Treatment IP Over EU Branch Objections
• Whistleblowing Eye Doc Asks Justices To Save Kickback Law
• Judge Says Ex-Insys CEO Has To Repay $6M In Defense Fees
• Illumina Tells 5th Circ. FTC Merger Block Unconstitutional
• Sales Reps In The Operating Room: How To Manage The Risks
• Maine Hospital Workers Want Justices To Review Vax Mandate
• Dog Food Cos. Say 8th Circ. Should Rethink Remand Order
• Lewis Brisbois Says Device Maker Owes $1M In Legal Fees
• 3 Ways Justices' Disclosure Defenses Miss The Ethical Point
• Maternity Co. Twisted Facts In Trade Secrets Row, Court Told
• Morgan Lewis, Freshfields Build $108M Cell Biology Co. Deal
• Otsuka Wins Block On Cancer Drug Lonsurf's Generic Version
• Brita Overhypes Devices' Water Filtering Abilities, Suit Says
• Implant Co. Says Whistleblower FCA Suits Unconstitutional
• Forte Investor Accuses Directors Of Stifling Stockholder Votes
• Delaware Federal Judge Upholds UCB's Epilepsy Drug Patent
• Red Cross Says DOJ Wrong On Antitrust Immunity
• Monsanto Wins Roundup Venue Fight At Mo. High Court
• Insys Trust Wants Insurer To Pay Share Of Ch. 11 Settlement
• Humana, Aetna Can't Return Seroquel Suit To Calif. Court
• Fla. Pharmacy Says Obesity Drug Suit Is Preempted By FDCA
• Fed. Circ. Won't Revive Cancer IP, To Newman's Dismay
• Home Health Co. Owner Admits To Hiding $2M From IRS
• IPR Pointers In Recent PTAB Discretionary Denials
• 5th Circ. Upholds Abortion Pill's Approval, But Backs Limits
• Aurora Health Strikes $12.25M Deal To End Pixel Privacy Suit
• Don't Ban The Apple Watch, Groups Urge Fed. Circ.
• Foam Co. Slams Insurers' Bid To Toss PFAS Coverage Suit
• UPenn Docs Seek To Dodge $183M Birth Injury Verdict
• 4th Circ. Resurrects FCA Suit Over Walgreens Medicaid Fraud
• DePuy Counsel Says Spinal IP Suit Is Worthy Of Atty Fees
• Life Sentence Advised For Ex-CEO In $187M Medicare Fraud
• Pa. Lab Owner Gets Prison For Medicare Kickback Scheme
• Limitations In Seeking Trade Dress With Patent Protection
• 7th Circ. Refuses To Revisit $10M Drug Co. Coverage Ruling
• Utah Man Arrested 3 Years After COVID Cure Charges
• Catalent Brass Face Investor Suit Over COVID Vaccine Woes
• Becton Dickinson Escapes Ex-Worker's Obesity Bias Suit
• Proskauer Faces Trial For Alleged $636M Error As Talks Fail
• Teva Scores FCA Trial Delay, Kickback Law Appeal At 1st Circ.
• Drug Negotiation Suits Reflect Lobbying Failures, HHS Says
• 3rd-Party Releases In Ch. 11 May Die At Supreme Court
• Investors Sue Viatris Brass For Selling Off Biosimilars
• HIV Drug Buyers Want New Antitrust Trial
• Implications Of PTAB's Decision On Scope Of Work Product
• Life Sciences Biz Paying Up To $200M For CBD Drugmaker
• Orrick Slapped With Data Breach Suit
• Genentech Denied Quick Exit In 'Uncertain' 401(k) Fees Suit
• Cellino Fights Atty's Bid To Block Fees In J&J Mesh MDL
• Ill. Judge Unfreezes Ex-Outcome Health CEO's $5M
• Ohio Justices Sink Challenge To Abortion Rights Referendum
• Walmart Can't Fry Fish Oil Supplement False Ad Lawsuit
• NJ Judge Won't Impose 6 Month Ch. 11 Bar On J&J Talc Unit
• 7th Circ. Won't Undo CR Bard's $3.3M Vein Filter Verdict Loss
• Fed. Circ. Backs PTAB's Trim Of Urine Test Patent
• Biden Admin Targets Purdue, 'Ghost Guns' In Shadow Dockets
• Animal Health Co. Merck Can't Sink Pet Microchip Lawsuit
• Amgen, Horizon Say FTC Constitutionality Key To Merger Row
• Kaiser Doctors Didn't Flag Cancerous Mass, Wash. Man Says
• 8th Circ. Affirms Coloplast's Win In Mesh Injury Suit
• High Court Told Fintiv Rule Leads To 'Arbitrary Outcomes'
• DOJ Probes UnitedHealth Unit's $3.3B Amedisys Deal
• Splenda Pans Scientist's Cancer Claims As 'Fearmongering'
• 2 Firms Guide HDL Therapeutics' $480M SPAC Merger
• SEC Investigating Illumina-Grail Deal And Management Teams
• Amyris Ok'd To Tap Part Of $190M DIP Loan For Quick Ch. 11
• Comparing US And EU Approaches To Health AI Regulation
• Caregiver Flexibility Is Crucial For Atty Engagement, Retention
• Standing Issues Prevail In Wake Of Calif. Competition Ruling
• UK Litigation Roundup: Here's What You Missed In London
• Henrietta Lacks' Family Sues Ultragenyx Over Stolen Cells
• Fed. Circ. Wary Of Masimo Bid To Revive IP In Apple Feud
• WilmerHale Wants To Skip Ch. 11 Client Disclosures
• Cancer Drug's Delay Amounts To Extortion, Clinic Says
• Ex-Dental Co. Worker's Pregnancy Bias Claims Head To Trial
• Faruqi & Faruqi Will Lead Investors In COVID Drug Claims Suit
• Gilead Sciences Inks $247M Deal For HIV Antitrust Claims
• Justices Halt Purdue Ch. 11 Plan Over Sackler Releases
• Blue Cross Can Subpoena Lab Exec's Atty In Fraud Suit
• 1st Circ. Affirms $1.7M Award To NuVasive In Noncompete Suit
• MoCRA Will Give Cosmetics Litigation A Makeover
• Duke Paid Female Scientist Less Than Male Peers, Suit Says
• High Court Ruling No Help To Ex-Aegerion Rep, Feds Say
• Bio Venture Amyris Files Ch. 11 With $1.1B In Debt
• Juul's $255M MDL Gets Nod, Judge Mulls $76.5M Atty Fee Bid
• AstraZeneca Unit Dodges PTAB Review For $2B Cancer Drug
• Justices Urged To Skip Eligibility Case For Blood Test Patents
• Del. Justices Say Pharma Co. Buyout Of Drugmaker Was Fair
• PTAB Reform Bill Won't Help Cut Drug Prices, Groups Say
• Ex-VP Says Medical Biz Fired Her For Raising Diversity Issues
• Pharmacy Group Wants Last PharmacyChecker Claim Nixed
• What Justices' Pork Ruling Means For Interstate Cannabis
• Pfizer Says 401(k) Mismanagement Claims Must Be Tossed
• Surgery Patient Says His Arthrex Shoulder Device Broke
• Greenberg Traurig Adds 2 Reed Smith Health Care Pros
• Fed. Circ. Told Apple Watch Ban Could Turn ITC 'Meaningless'
• Ohioans Reject Proposal Viewed As Abortion Rights Hurdle
• Individual Inventors Face Rough Day At Federal Circuit
• NC Republicans Fight Shutdown Bid To Abortion Law Sections
• Takeda Agrees To Pay Texas $42M Over ADHD Drug Marketing
• In-Office Engagement Is Essential To Associate Development
• Holland & Knight Brings On Reed Smith Product Liability Duo
• Complex Hemp Processes Need Nimble Regulatory Approach
• PTAB Invalidates Some Claims In Stryker Bone Plate Patent
• South Carolina Joins Wave Of PFAS Suits Against 3M, DuPont
• Judge Backs Acorda's $16.6M Award In MS Drug Row
• Doc Seeks $46M In Damages After Penile Implant Trial Win
• Sorrento OK'd For New $100M Ch. 11 DIP Loan In Texas
• J&J Metal Hip Implant Suits Consolidated In Wash. State Court
• NC Psychologist Settles FCA Suit Over Brain-Testing Device
• Nektar Says Eli Lilly Botched Autoimmune Drug Trials
• 3 Firms Steer $570M Merger Of Pharmacy Management Cos.
• Biotech Firm Says It Was Stiffed Over COVID-19 Tests
• Mayo Clinic Beats Christian Workers' Bias Suits Over Vaccine
• Natera, CareDx Both Blocked From Making False Ad Claims
• Fed. Circ. Tells PTAB To Rethink Medtronic Patent Ruling
• 2nd Circ. Lets Conn. Vaccine Mandate Suit Survive On 1 Claim
• A Judge's Pitch To Revive The Jury Trial
• What Patent Bills Would Mean For Infringement Litigation
• Texas Judge Blocks Abortion Bans In Medical Emergencies
• US Chamber Says Big Pharma Can't Be Blamed For Terrorism
• Kentucky Trans Youth Urge Quick Ruling On Gender Care Ban
• PTAB Has To Eye Hormone Drug Fight Again, Vidal Finds
• Purdue Pharma Asks Justices To Reject Ch. 11 Challenge
• IRS, Treasury To Float Regs On Scope Of Drug Negotiation Tax
• Amazon And Pharma Cos. Sued Over Tainted Eye Drops
• FTC Defends Illumina-Grail Block — And Its Constitutionality
• Insurer Says No Coverage For $5.4M Texas Contamination Suit
• Ex-Hospital Employee Defends COVID Vax Bias Suit
• DOJ Says Red Cross Not Immune From Platelet Antitrust Suit
• Pharma Cos. Can't Trim Gout Drug Antitrust Claims
• JPML Centralizes Insulin Price-Fixing Suits In New Jersey
• NC Lab Will Pay $1.9M To Settle FCA Kickback Case
• J&J Can't Appeal Dismissal Bids In Tylenol Birth Defect MDL
• Fla. Hospital Patients Say They Were Targeted In Data Breach
• Ohio Judge Trims Tech Co.'s $3M E-Commerce IP Theft Suit
• Negotiating AI-Life Sciences Partnerships To Minimize IP Risk
• How To Recognize And Recover From Lawyer Loneliness
• Feds Granted Protected Mass. Patient Data In Lead Test Case
• UK Litigation Roundup: Here's What You Missed In London
• Becton Investors Get Cert. In Securities Suit Over Pump Recall
• NJ Panel Backs DEP Standards For 'Forever Chemicals'
• Becton's Pyxis Safe Targeted With Ill. Biometric Claims
• 9th Circ. Revives Atty's FCA Suit Against Valeant Over Apriso
• Teva Signs $126M Opioid Deal With Hospitals
• Euro Industry Groups Voice Opposition To PFAS Ban
• Del. Court Sends Patent Suit Against PacBio To Calif.
• Sotera Blasts Shareholder Suit Over $363M Emissions Verdict
• Supplement Co., Manager Fined $1M For COVID Cure Claims
• Litigation Funding Disclosure Should Be Mandatory
• 4 Employer Action Steps For New Mental Health Parity Rules
• Recalling USWNT's Legal PR Playbook Amid World Cup Bid
• Judge Tosses Firm's Bid To Boot Future J&J Talc Claims Rep
• FDA Snags Early Win In Vanda Gastro Drug Review Challenge
• Former Pharma CFO's Ex-Girlfriend Fined For Insider Trading
• Medtronic Can't Yet Ditch Rival's Surgical Market Antitrust Suit
• Advocacy Groups, Scholars Back FTC Against Illumina Appeal
• 9th Circ. Nixes Injunction On Guam Abortion-Consultation Law
• Blank Spot On Form Dooms $637K VA Equipment Lease Claim
• Eli Lilly And Novo Nordisk Sued Over Risks Of Diabetes Drugs
• J&J Unit's Talc Claimants Seek Temporary Bar On 3rd Ch. 11
• Shuttered Philly Pharmacies To Pay $3.5M To End FCA Claims
• Hedge Fund Priest Tells High Court SEC Case Chills Speech
• Latham-Led SK Capital Secures $800M For 2nd Catalyst Fund
• What Companies Must Know About Product Recalls
• The Hottest Health And Life Sciences Policy In 2023's 2nd Half
• Genentech Sues Sandoz Over Generic Lung Disease Drug
• AstraZeneca Sets Aside $510M For Bristol-Myers Patent Deal
• Families Seek Cert In Fla. Trans Health Care Suit
• Ill. Judge Urges Deal Over Ex-Outcome CEO's Frozen $5M
• PG&E Sued Over Smoke Health Harms Of Dixie, Fly Wildfires
• Biden Wants To Spend More Money On US Inventions
• Sorrento Hits Snag On $200M Scilex Stock Sale In Ch. 11
• Forced-Labor Probes Call Out 2 Chinese Companies
• Proskauer, Investor To Try Mediation Over Alleged $636M Error
• Judge Backs Moderna On Key Patent Terms In Pfizer Vax Row
• State Farm Saves Billions With Minority Fraud Plot, Co. Says
• It's Not You, It's Me: Breaking Up With Mass. FCA Prosecutors
• Fresenius Can't Kill Nausea Drug IP Claims As Indefinite
• Likely Outcomes In PTAB Director Reviews After End Of POP
• FTC Hails Nix Of $875M Reproductive Health Tech Deal
• Fla. Co. Fined $7.6M Over False Smoking Cessation Claims
• Thermo Fisher Settles Suit Over Use Of Henrietta Lacks' Cells
• Oncology Co. Boosts Balance Sheet By $1B With EQRx Buy